Help & Support
BPL, the maker of COAGADEX, has been producing plasma-based products for more than 60 years.
We have several resources that can answer questions and provide support…all you need to do is ask!
If you have a prescription for COAGADEX and are having difficulty paying for your medication, BPL may be able to help.
- The COAGADEX Copay Support Program will provide up to $12,000 per calendar year to cover out-of-pocket expenses for your COAGADEX prescription.
- Some restrictions apply. To see if you qualify, visit MyCoagadex.Medmonk.com.
BPL is committed to helping patients find answers to their questions about COAGADEX. This includes helping patients with:
- Copay assistance
- Issues with insurance coverage
- Prior authorizations and appeals
- Other questions related to COAGADEX
Talking with Your Doctor About COAGADEX
If you want to talk to your healthcare provider about COAGADEX, the COAGADEX Guide can help. Read the information on the front and answer the questions on the back. Then show the sheet to your healthcare provider and tell them that you’d like to talk about whether COAGADEX is right for you.
Indications for COAGADEX
COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children (aged 12 years and above) with hereditary factor X deficiency for:
- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding in patients with mild hereditary factor X deficiency
Limitation of Use
Perioperative management of bleeding in major surgery in patients with moderate and severe hereditary factor X deficiency has not been studied.
Important Safety Information for COAGADEX
COAGADEX is contraindicated in patients with known hypersensitivity to any of the components of the product.
Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately and contact their physician.
The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.
COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.
In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.
Please see Full Prescribing Information for complete prescribing details.